Felix Lauffer1, Tilo Biedermann2. 1. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Biedersteinerstr. 29, 80802, München, Deutschland. felix.lauffer@mri.tum.de. 2. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Biedersteinerstr. 29, 80802, München, Deutschland.
Abstract
BACKGROUND: Atopic dermatitis is a common chronic inflammatory skin disease and has a major impact on patient's quality of life. Janus kinase inhibitors were recently approved for the treatment of atopic dermatitis. OBJECTIVES: To summarize current data on efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis as well as guidelines for the use in clinical practice. MATERIALS AND METHODS: Summary and assessment of currently available data. RESULTS: Three Janus kinase inhibitors are approved for the treatment of moderate to severe atopic dermatitis: baricitinib, upadacitinib and abrocitinib. Clinical trials and first real-life data demonstrate rapid and strong reduction of pruritus and clinical signs of atopic dermatitis as well as improvement of patient's quality of life. The safety profile is favorable, although data on long-term safety especially for the treatment of atopic dermatitis patients are still lacking. CONCLUSIONS: Janus kinase inhibitors enrich the therapeutic portfolio for the treatment of atopic dermatitis. When carefully taking into consideration contraindications, side effects, and necessary laboratory controls, they represent a highly effective and safe treatment option for affected patients.
BACKGROUND: Atopic dermatitis is a common chronic inflammatory skin disease and has a major impact on patient's quality of life. Janus kinase inhibitors were recently approved for the treatment of atopic dermatitis. OBJECTIVES: To summarize current data on efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis as well as guidelines for the use in clinical practice. MATERIALS AND METHODS: Summary and assessment of currently available data. RESULTS: Three Janus kinase inhibitors are approved for the treatment of moderate to severe atopic dermatitis: baricitinib, upadacitinib and abrocitinib. Clinical trials and first real-life data demonstrate rapid and strong reduction of pruritus and clinical signs of atopic dermatitis as well as improvement of patient's quality of life. The safety profile is favorable, although data on long-term safety especially for the treatment of atopic dermatitis patients are still lacking. CONCLUSIONS: Janus kinase inhibitors enrich the therapeutic portfolio for the treatment of atopic dermatitis. When carefully taking into consideration contraindications, side effects, and necessary laboratory controls, they represent a highly effective and safe treatment option for affected patients.
Authors: Thomas Werfel; Annice Heratizadeh; Werner Aberer; Frank Ahrens; Matthias Augustin; Tilo Biedermann; Thomas Diepgen; Regina Fölster-Holst; Julia Kahle; Alexander Kapp; Katja Nemat; Eva Peters; Martin Schlaeger; Peter Schmid-Grendelmeier; Jochen Schmitt; Thomas Schwennesen; Doris Staab; Claudia Traidl-Hoffmann; Ricardo Werner; Andreas Wollenberg; Margitta Worm; Hagen Ott Journal: J Dtsch Dermatol Ges Date: 2021-01 Impact factor: 5.584
Authors: K Reich; A M DeLozier; F P Nunes; J P Thyssen; L F Eichenfield; A Wollenberg; J A Ross Terres; S D Watts; Y-F Chen; E L Simpson; J I Silverberg Journal: J Dermatolog Treat Date: 2020-11-22 Impact factor: 3.230